A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
← catalyst calendarSponsored by Oncolytics Biotech (industry) · ONCY — their whole pipeline →. With PrECOG, LLC..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
48actual
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-06-10 | actual | When the study began enrolling |
| Primary completion | 2022-08-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2020-01-02 | actual | When this record first appeared on the registry |
| Results posted | 2025-01-16 | actual | When the sponsor posted results to the registry |
| Record updated | 2025-01-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Breast Cancer Metastatic
Interventions
- Drug: Paclitaxel
- Biological: Pelareorep
- Drug: Avelumab
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate
measured at week 16
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2022-07-21 · 741 KB · Prot_000.pdf
Statistical Analysis Planposted 2022-08-18 · 637 KB · SAP_001.pdf
Permalink · ONCY's whole pipeline · Catalyst calendar · Every registered study · What changed